No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Specialty Retail
Through its subsidiaries, Fielmann Aktiengesellschaft focuses on investing in and managing businesses within the optics and hearing aid sectors. It produces and distributes an extensive array of visual aids, such as spectacles, frames, lenses, sunglasses, contact lenses, and related accessories. In addition to these optical offerings, Fielmann provides hearing aids, their accompanying accessories, and diverse general merchandise. By the close of 2021, its retail footprint encompassed 693 stores, predominantly in Germany (610), along with significant operations in Spain (87), Italy (43), Switzerland (45), Austria (38), Poland (37), Slovenia (32), Luxembourg (3), and an additional 15 outlets scattered across other European nations. An additional 78 smaller establishments are maintained throughout Eastern Europe. Its product range is also available for purchase via its digital storefronts. Founded in 1972, the firm's headquarters are situated in Hamburg, Germany. Fielmann Aktiengesellschaft operates as a subsidiary of Korva SE.
www.fielmann-group.comNo one on the platform currently holds FIE.DE.
No tracked institution reports a position in FIE.DE as of their last filing.
No one on the platform has traded FIE.DE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 13.8% | 16.3% | 20.4% | — | — | — |
| Rev. Growth % | 7.6% | 11.3% | ||||
| Profit Margin % | 8.4% | 7.1% | 9.1% | |||
| Free Cash Flow Margin % | 14.5% | 13.0% | 12.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.5B | +3.1% | $2.47 | $2.31–$2.62 | — | 9 |
| 2027 | $2.7B | +5.2% | $2.79 | $2.46–$3.10 | — | 9 |
| 2028 | $2.8B | +5.5% | $3.16 | $2.60–$3.61 | — | 6 |
| 2029 | $3.0B | +7.2% | $3.13 | $3.05–$3.24 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-27 | $0.65 | $1.31 | +101.5% |
| 2026-04-30 | $0.66 | $0.66 | +0.0% |
| 2026-02-27 | $0.14 | $0.57 | +307.1% |
| 2025-11-06 | $0.14 | $0.62 | +342.9% |
| 2025-05-08 | $0.62 | $0.62 | +0.0% |
| 2024-11-01 | $0.70 | $0.47 | -32.9% |
| -1.81% |
| $3.0B |
| — |
| BZ7A.FBumrungrad Hospital Public Company Limited | $5.05 | +1.41% | $4.0B | — |
| DMP.DEDermapharm Holding SE | $37.80 | -0.26% | $1.9B | — |
Source: Financial Modeling Prep · peers by sector/industry